Biologics News from NASDAQ

December 19, 2016
The Center for Biosimilars Staff

Annual changes to the NASDAQ Biotechnology Index

Last week Nasdaq announced the results of the annual re-ranking of the NASDAQ Biotechnology Index, which

went into effect prior to today's market open.

The following 21 securities have been added to the Index:

Exchange

SYMBOL

COMPANY NAME

Nasdaq

AIMT

Aimmune Therapeutics, Inc.

Nasdaq

ARLZ

Aralez Pharmaceuticals Inc.

Nasdaq

AVXS

AveXis, Inc.

Nasdaq

BGNE

BeiGene, Ltd.

Nasdaq

BOLD

Audentes Therapeutics

Nasdaq

CLCD

CoLucid Pharmaceuticals

Nasdaq

CLSD

Clearside Biomedical, Inc.

Nasdaq

CYTK

Cytokinetics, Incorporated

Nasdaq

EDIT

Editas Medicine, Inc.

Nasdaq

GBT

Global Blood Therapeutics

Nasdaq

ITCI

Intra-Cellular Therapies

Nasdaq

LOXO

Loxo Oncology, Inc.

Nasdaq

MNOV

Medicinova Inc

Nasdaq

NERV

Minerva Neurosciences

Nasdaq

NH

NantHealth, Inc.

Nasdaq

NTLA

Intellia Therapeutics, Inc.

Nasdaq

NVCR

NovoCure Limited

Nasdaq

ONVO

Organovo Holdings Inc

Nasdaq

OPK

OPKO Health, Inc.

Nasdaq

PRTK

Paratek Pharmaceuticals, Inc.

Nasdaq

RGNX

REGENXBIO Inc.

The Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® (NASDAQ®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB).

As a result of the re-ranking, the following 37 securities will be removed from the Index:

Exchange

SYMBOL

COMPANY NAME

Nasdaq

ADHD

Alcobra Ltd.

Nasdaq

ADVM

Adverum Biotechnologies, Inc.

Nasdaq

AFMD

Affimed N.V.

Nasdaq

AGTC

Applied Genetic Technologies Corporation

Nasdaq

ANTH

Anthera Pharmaceuticals, Inc.

Nasdaq

CARA

Cara Therapeutics, Inc.

Nasdaq

CASC

Cascadian Therapeutics, Inc.

Nasdaq

CHMA

Chiasma, Inc.

Nasdaq

CMRX

Chimerix, Inc.

Nasdaq

CNCE

Concert Pharmaceuticals, Inc.

Nasdaq

CXRX

Concordia International Corp.

Nasdaq

DNAI

ProNAi Therapeutics, Inc.

Nasdaq

DRNA

Dicerna Pharmaceuticals, Inc.

Nasdaq

DRRX

DURECT Corporation

Nasdaq

ECYT

Endocyte, Inc.

Nasdaq

EGLT

Egalet Corporation

Nasdaq

FLKS

Flex Pharma, Inc.

Nasdaq

IMDZ

Immune Design Corp.

Nasdaq

IMGN

ImmunoGen, Inc.

Nasdaq

INFI

Infinity Pharmaceuticals, Inc.

Nasdaq

ITEK

Inotek Pharmaceuticals Corporation

Nasdaq

KMPH

KemPharm, Inc.

Nasdaq

LIFE

aTyr Pharma, Inc.

Nasdaq

MNKD

MannKind Corporation

Nasdaq

NDRM

NeuroDerm Ltd.

Nasdaq

NEOS

Neos Therapeutics, Inc.

Nasdaq

OCUL

Ocular Therapeutix, Inc.

Nasdaq

OREX

Orexigen Therapeutics, Inc.

Nasdaq

OSIR

Osiris Therapeutics, Inc.

Nasdaq

OVAS

OvaScience Inc.

Nasdaq

QURE

uniQure N.V.

Nasdaq

RGLS

Regulus Therapeutics Inc.

Nasdaq

SCLN

SciClone Pharmaceuticals, Inc.

Nasdaq

TKAI

Tokai Pharmaceuticals, Inc.

Nasdaq

TTPH

Tetraphase Pharmaceuticals, Inc.

Nasdaq

VTL

Vital Therapies, Inc.

Nasdaq

ZFGN

Zafgen, Inc.